ワクチン技術の世界市場レポート2025年

ワクチン技術の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.1%で907億米ドルに成長します。このような将来の成長は、mRNAベースのワクチン需要の高まり、個別化ワクチン開発への投資の増加、がん予防接種への重点化、慢性疾患の負担増、ワクチンの安全性に対する社会的理解の向上などによってもたらされます。予測期間中に予想される主な動向としては、mRNAおよびDNAワクチンプラットフォームの出現、ナノ粒子ベースの送達方法の進歩、混合ワクチンの使用の増加、耐熱性製剤の普及、針を使わない送達システムの革新などが挙げられます。

感染症の蔓延は、今後数年間におけるワクチン技術市場の拡大を牽引すると予想されます。感染症は、細菌、ウイルス、真菌、寄生虫などの有害な微生物によって引き起こされる病気で、ある個人から別の個人に感染する可能性があります。これらの疾病の増加は、国境を越えた病原体の拡散を加速させる世界の旅行の増加に大きく起因しています。ワクチン技術は、感染症を予防・制御する標的免疫応答を誘発することにより、感染症対策に役立っています。これらの技術は、疾病の蔓延と重症化を抑制することで公衆衛生に貢献し、全体的なヘルスケア成果を向上させる。例えば、2024年2月、英国健康安全保障局は、イングランドにおける結核患者が2023年には4,850人になり、2022年の4,380人から10.7％増加したと報告しました。このような感染症の急増は、ワクチン技術市場の成長を促進する重要な要因です。

ワクチン技術分野の主要企業は、予防接種率を高め、株不一致のリスクを軽減するために、4価インフルエンザワクチンなどの先進ソリューションの開発を優先しています。これらのワクチンは、4種類のインフルエンザ・ウイルス株（2種類のインフルエンザA型と2種類のインフルエンザB型）を予防するように設計されており、従来の3価ワクチンよりも幅広い予防効果が期待できます。例えば、2025年2月、インドの製薬会社ザイダス・ライフサイエンシズは、4価インフルエンザ・ワクチンであるVaxiFlu-4を発表しました。このワクチンは、A型とB型の両方を含む4種類のインフルエンザ株に対する季節性防御を提供します。単回筋肉内注射として投与され、成人と小児の両方に適しており、より包括的な株カバーを提供することで季節性インフルエンザの影響を軽減するのに役立ちます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のワクチン技術：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のワクチン技術市場：成長率分析
• 世界のワクチン技術市場の実績：規模と成長, 2019-2024
• 世界のワクチン技術市場の予測：規模と成長, 2024-2029, 2034F
• 世界のワクチン技術：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界のワクチン技術市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 組み換え体または複合体またはサブユニット
• 不活性化
• 生弱毒化
• トキソイド
• 世界のワクチン技術市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非経口
• 経口
• 経鼻
• 世界のワクチン技術市場：疾患適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 感染性疾患
• 非感染性疾患
• 世界のワクチン技術市場：年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児
• 大人
• 世界のワクチン技術市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と薬局
• 政府サプライヤー
• その他の流通チャネル
• 世界のワクチン技術市場、組換え体または複合体またはサブユニット、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• タンパク質サブユニットワクチン
• ウイルス様粒子（VLP）ワクチン
• 糖複合体ワクチン
• 組み換えベクターワクチン
• 世界のワクチン技術市場、不活性化、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 全ウイルス不活化ワクチン
• スプリットウイルス不活化ワクチン
• 精製不活化ワクチン
• 世界のワクチン技術市場、生弱毒化菌、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• ウイルス生弱毒化ワクチン
• 細菌生弱毒化ワクチン
• 世界のワクチン技術市場、トキソイド、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• ジフテリアトキソイドワクチン
• 破傷風トキソイドワクチン

第7章 地域別・国別分析

• 世界のワクチン技術市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のワクチン技術市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ワクチン技術市場：競合情勢
• ワクチン技術市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• GSK plc
• Moderna Inc.
• CSL Limited
• Bharat Biotech International Limited
• Bavarian Nordic A/S
• Takeda Pharmaceutical Company Limited
• Sinovac Biotech Ltd.
• Emergent BioSolutions Inc.
• Valneva SE
• Novavax Inc.
• Dynavax Technologies Corporation
• CureVac N.V.
• Inovio Pharmaceuticals Inc
• Mitsubishi Tanabe Pharma Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ワクチン技術市場2029：新たな機会を提供する国
• ワクチン技術市場2029：新たな機会を提供するセグメント
• ワクチン技術市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Vaccine technologies encompass the scientific techniques and tools utilized to create, manufacture, and administer vaccines that activate the immune system to identify and combat pathogens such as viruses, bacteria, or other harmful microorganisms. The primary goal of these technologies is to safely trigger immunity, thereby preventing diseases and helping to control the spread of infections.

There are several key types of vaccine technologies, including recombinant, conjugate, subunit, inactivated, live attenuated, and toxoid vaccines. These vaccines work by using specific components of a virus or bacterium-such as proteins or sugars-instead of the entire pathogen to safely elicit an immune response. Vaccines are delivered through various routes like parenteral, oral, and nasal methods, and are used for both infectious and non-infectious disease applications. They are suitable for all age groups, from children to adults, and are distributed through multiple channels including hospitals, retail pharmacies, government programs, and other providers.

The vaccine technologies market research report is one of a series of new reports from The Business Research Company that provides vaccine technologies market statistics, including vaccine technologies industry global market size, regional shares, competitors with a vaccine technologies market share, detailed vaccine technologies market segments, market trends and opportunities, and any further data you may need to thrive in the vaccine technologies industry. This vaccine technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vaccine technologies market size has grown rapidly in recent years. It will grow from $55.59 billion in 2024 to $61.38 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. Growth during the historical period was supported by increasing cases of infectious diseases, enhanced government funding for vaccine-related research, pandemic outbreaks, heightened public awareness of vaccines' advantages, and the broadening of immunization initiatives.

The vaccine technologies market size is expected to see rapid growth in the next few years. It will grow to $90.7 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. This future growth will be driven by the rising demand for mRNA-based vaccines, increased investments in personalized vaccine development, heightened emphasis on cancer immunization, a growing burden of chronic illnesses, and improved public understanding of vaccine safety. Key trends anticipated during the forecast period include the emergence of mRNA and DNA vaccine platforms, advancements in nanoparticle-based delivery methods, increased use of combination vaccines, the uptake of thermostable formulations, and innovations in needle-free delivery systems.

The growing prevalence of infectious diseases is anticipated to drive the expansion of the vaccine technologies market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can be transmitted from one individual to another. The rise in these diseases is largely attributed to increased global travel, which accelerates the spread of pathogens across borders. Vaccine technologies help in combating infectious diseases by eliciting targeted immune responses that prevent and control infections. These technologies contribute to public health by reducing the spread and severity of diseases, thereby improving overall healthcare outcomes. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England rose to 4,850 in 2023, marking a 10.7% increase from 4,380 cases in 2022. This surge in infectious diseases is a key factor propelling the growth of the vaccine technologies market.

Leading companies in the vaccine technologies sector are prioritizing the development of advanced solutions such as quadrivalent influenza vaccines to enhance immunization coverage and reduce the risk of strain mismatch. These vaccines are designed to protect against four influenza virus strains-two influenza A and two influenza B-offering broader protection than traditional trivalent vaccines. For instance, in February 2025, Zydus Lifesciences, an India-based pharmaceutical firm, introduced VaxiFlu-4, a quadrivalent influenza vaccine. This vaccine provides seasonal protection against four strains of influenza, including both types A and B. It is administered as a single-dose intramuscular injection and is suitable for both adults and children, helping to lessen the impact of seasonal influenza by offering more comprehensive strain coverage.

In December 2023, AstraZeneca plc, a UK-based biopharmaceutical company, acquired Icosavax Inc. for $1.1 billion. This acquisition was aimed at strengthening AstraZeneca's respiratory vaccine portfolio through the addition of Icosavax's innovative protein virus-like particle (VLP) platform. This platform includes a phase III-ready combination vaccine candidate, IVX-A12, which targets both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Icosavax is a US-based biotechnology company that focuses on the development of VLP-based vaccines for respiratory illnesses.

Major players in the vaccine technologies market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc, Sanofi S.A., AstraZeneca plc, Novartis AG, GSK plc, Moderna Inc., CSL Limited, Bharat Biotech International Limited, Bavarian Nordic A/S, Takeda Pharmaceutical Company Limited, Sinovac Biotech Ltd., Emergent BioSolutions Inc., Valneva SE, Novavax Inc., Dynavax Technologies Corporation, CureVac N.V., Inovio Pharmaceuticals Inc, and Mitsubishi Tanabe Pharma Corporation.

North America was the largest region in the vaccine technologies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vaccine technologies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vaccine technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vaccine technologies market consists of revenues earned by entities by providing services such as vaccine research and development, formulation and testing, clinical trials management, regulatory support, manufacturing process optimization, and distribution logistics for vaccines. The market value includes the value of related goods sold by the service provider or included within the service offering. The vaccine technologies market also includes sales of mRNA vaccines, viral vector vaccines, protein subunit vaccines, and related raw materials and reagents used in vaccine development and production. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vaccine Technologies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vaccine technologies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vaccine technologies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vaccine technologies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Recombinant Or Conjugate Or Subunit; Inactivated; Live Attenuated; Toxoid
• 2) By Route Of Administration: Parenteral; Oral; Nasal
• 3) By Disease Indication: Infectious Diseases; Non-Infectious Diseases
• 4) By Age Group: Pediatric; Adults
• 5) By Distribution Channel: Hospital And Retail Pharmacies; Government Suppliers; Other Distribution Channels
• Subsegments:
• 1) By Recombinant Or Conjugate Or Subunit: Protein Subunit Vaccines; Virus-Like Particle (VLP) Vaccines; Glycoconjugate Vaccines; Recombinant Vector Vaccines
• 2) By Inactivated: Whole-Virus Inactivated Vaccines; Split-Virus Inactivated Vaccines; Purified Inactivated Vaccines
• 3) By Live Attenuated: Viral Live Attenuated Vaccines; Bacterial Live Attenuated Vaccines
• 4) By Toxoid: Diphtheria Toxoid Vaccines; Tetanus Toxoid Vaccines
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc; Sanofi S.A.; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vaccine Technologies Market Characteristics

3. Vaccine Technologies Market Trends And Strategies

4. Vaccine Technologies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Vaccine Technologies Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vaccine Technologies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vaccine Technologies Market Growth Rate Analysis
• 5.4. Global Vaccine Technologies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vaccine Technologies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vaccine Technologies Total Addressable Market (TAM)

6. Vaccine Technologies Market Segmentation

• 6.1. Global Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Or Conjugate Or Subunit
• Inactivated
• Live Attenuated
• Toxoid
• 6.2. Global Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parenteral
• Oral
• Nasal
• 6.3. Global Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Infectious Diseases
• Non-Infectious Diseases
• 6.4. Global Vaccine Technologies Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adults
• 6.5. Global Vaccine Technologies Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital And Retail Pharmacies
• Government Suppliers
• Other Distribution Channels
• 6.6. Global Vaccine Technologies Market, Sub-Segmentation Of Recombinant Or Conjugate Or Subunit, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Protein Subunit Vaccines
• Virus-Like Particle (VLP) Vaccines
• Glycoconjugate Vaccines
• Recombinant Vector Vaccines
• 6.7. Global Vaccine Technologies Market, Sub-Segmentation Of Inactivated, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Whole-Virus Inactivated Vaccines
• Split-Virus Inactivated Vaccines
• Purified Inactivated Vaccines
• 6.8. Global Vaccine Technologies Market, Sub-Segmentation Of Live Attenuated, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Viral Live Attenuated Vaccines
• Bacterial Live Attenuated Vaccines
• 6.9. Global Vaccine Technologies Market, Sub-Segmentation Of Toxoid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diphtheria Toxoid Vaccines
• Tetanus Toxoid Vaccines

7. Vaccine Technologies Market Regional And Country Analysis

• 7.1. Global Vaccine Technologies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vaccine Technologies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vaccine Technologies Market

• 8.1. Asia-Pacific Vaccine Technologies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vaccine Technologies Market

• 9.1. China Vaccine Technologies Market Overview
• 9.2. China Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vaccine Technologies Market

• 10.1. India Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vaccine Technologies Market

• 11.1. Japan Vaccine Technologies Market Overview
• 11.2. Japan Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vaccine Technologies Market

• 12.1. Australia Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vaccine Technologies Market

• 13.1. Indonesia Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vaccine Technologies Market

• 14.1. South Korea Vaccine Technologies Market Overview
• 14.2. South Korea Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vaccine Technologies Market

• 15.1. Western Europe Vaccine Technologies Market Overview
• 15.2. Western Europe Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vaccine Technologies Market

• 16.1. UK Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vaccine Technologies Market

• 17.1. Germany Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vaccine Technologies Market

• 18.1. France Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vaccine Technologies Market

• 19.1. Italy Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vaccine Technologies Market

• 20.1. Spain Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vaccine Technologies Market

• 21.1. Eastern Europe Vaccine Technologies Market Overview
• 21.2. Eastern Europe Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vaccine Technologies Market

• 22.1. Russia Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vaccine Technologies Market

• 23.1. North America Vaccine Technologies Market Overview
• 23.2. North America Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vaccine Technologies Market

• 24.1. USA Vaccine Technologies Market Overview
• 24.2. USA Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vaccine Technologies Market

• 25.1. Canada Vaccine Technologies Market Overview
• 25.2. Canada Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vaccine Technologies Market

• 26.1. South America Vaccine Technologies Market Overview
• 26.2. South America Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vaccine Technologies Market

• 27.1. Brazil Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vaccine Technologies Market

• 28.1. Middle East Vaccine Technologies Market Overview
• 28.2. Middle East Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vaccine Technologies Market

• 29.1. Africa Vaccine Technologies Market Overview
• 29.2. Africa Vaccine Technologies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vaccine Technologies Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vaccine Technologies Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vaccine Technologies Market Competitive Landscape And Company Profiles

• 30.1. Vaccine Technologies Market Competitive Landscape
• 30.2. Vaccine Technologies Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Vaccine Technologies Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. GSK plc
• 31.3. Moderna Inc.
• 31.4. CSL Limited
• 31.5. Bharat Biotech International Limited
• 31.6. Bavarian Nordic A/S
• 31.7. Takeda Pharmaceutical Company Limited
• 31.8. Sinovac Biotech Ltd.
• 31.9. Emergent BioSolutions Inc.
• 31.10. Valneva SE
• 31.11. Novavax Inc.
• 31.12. Dynavax Technologies Corporation
• 31.13. CureVac N.V.
• 31.14. Inovio Pharmaceuticals Inc
• 31.15. Mitsubishi Tanabe Pharma Corporation

32. Global Vaccine Technologies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vaccine Technologies Market

34. Recent Developments In The Vaccine Technologies Market

35. Vaccine Technologies Market High Potential Countries, Segments and Strategies

• 35.1 Vaccine Technologies Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Vaccine Technologies Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Vaccine Technologies Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer